<DOC>
	<DOCNO>NCT00315653</DOCNO>
	<brief_summary>The purpose clinical trial evaluate ability urinary Survivin mRNA measurement estimate risk bladder cancer time cystoscopy subject prior history bladder cancer present microscopic macroscopic hematuria .</brief_summary>
	<brief_title>Survivin Urine mRNA Assay Risk Bladder Cancer Study</brief_title>
	<detailed_description>Bladder cancer fourth common cancer men ninth common cancer woman , account 60,000 new case ~12,000 death North America 2004 . Cystoscopy urinary cytology standard care detection bladder cancer , cystoscopy expensive invasive , cytology low sensitivity . New , noninvasive , diagnostic tool bladder cancer detection develop , application clinical practice limit due low sensitivity specificity assay . Survivin , anti-apoptotic protein , capable regulating cell proliferation apoptotic cell death , over-expressed human cancer normal adult tissue . The purpose clinical trial evaluate ability urinary Survivin mRNA measurement estimate risk bladder cancer time cystoscopy subject prior history bladder cancer present microscopic macroscopic hematuria . This study design prospective , multicenter , double blind , clinical study subject &gt; 50 year old prior history bladder cancer confirm hematuria ( microscopic and/or macroscopic ) present urologist . The primary objective study estimate risk bladder cancer time cystoscopy subject &gt; 50 year old prior history bladder cancer confirm hematuria use urinary Survivin mRNA level . The secondary objective study comparison multivariate predictive algorithm use urinary Survivin mRNA level subject risk factor , age , sex , race , smoke history , estimation risk bladder cancer time cystoscopy subject &gt; 50 year old prior history bladder cancer confirm hematuria use urinary Survivin mRNA level alone .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Able understand sign Informed Consent ; Age &gt; 50 year old ; Males females ; Subjects must confirm microhematuria , define positive urine reagent strip test blood ( i.e . find `` Trace '' high amount blood ) and/or &gt; 3 RBC per high power field microscopic examination , macrohematuria , define visible blood urine sample ; All subject must schedule undergo cystoscopy evaluation ; All subject must upper tract image perform within +/ 4 week cystoscopic evaluation . Previous history bladder cancer ; Previous history cancer except nonmelanoma skin cancer ; Prior pelvic radiation ; Active urinary vaginal infection ; Any evidence vaginal rectal bleeding ; Currently receive chemotherapy cyclophosphamide methotrexate ; Unable provide inform consent high risk subject may comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Cancer Bladder</keyword>
	<keyword>Bladder Tumors</keyword>
	<keyword>Cancer Bladder</keyword>
	<keyword>Neoplasms , Bladder</keyword>
</DOC>